Surrozen, Inc. Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
November 15, 2021 at 08:00 am EST
Share
Surrozen, Inc. announced that data from its liver disease program, including preclinical studies of SZN-043 showing improved liver metabolic function, were presented during The Liver Meeting 2021, organized by the American Association for the Study of Liver Diseases (AASLD) and held November 12-15. In a poster titled, ?SZN-043 Improves Liver Metabolic Function in a Mouse Preclinical Model,? the data showed that methacetin quantification after IV dosing in mice can be used to demonstrate that SZN-043 can quickly increase liver function and that the duration of this effect is transient but can last beyond effects on gene regulation. The poster titled ?Non-Invasive Pharmacodynamic Markers of SZN-043 Target Engagement and Wnt Pathway Activation,? analyzed the effect of SZN-043 on non-invasive pharmacodynamic markers of target occupancy and Wnt/?-catenin activation in normal mice treated with a single dose of SZN-043 at increasing doses. Target occupancy was evaluated by measuring serum alkaline phosphatase (ALP) as SZN-043 binds to the ASGR receptor and increases ALP serum concentration by interfering with ALP elimination occurring through the ASGR receptor. Wnt/?-catenin activation was evaluated by measuring serum leukocyte cell-derived chemotaxin-2 (LECT2), a direct Wnt target gene. The results showed that serum ALP concentrations and LECT2 concentrations increased in a dose-dependent manner and that these markers can be used as non-invasive pharmacodynamic markers of SZN-043 target occupancy and Wnt activation, respectively. Consistent with the observation of interfering with ALP elimination, SZN-043 did not affect ALP gene expression.
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the bodyâs response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.
Surrozen, Inc. Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases